Discovery of Potential Targets of Triptolide Through Inverse Docking in Ovarian Cancer Cells

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2020 Mar 29

PMID 32219016

Authors

Qinhang Wu

Gang Bao

Yang Pan

Xiaoqi Qian

Furong Gao

Affiliations

Soon will be listed here.

Abstract

Triptolide (TPL) is proposed as an effective anticancer agent known for its anti-proliferation of a variety of cancer cells including ovarian cancer cells. Although some studies have been conducted, the mechanism by which TPL acts on ovarian cancer remains to be clearly described. Herein, systematic work based on bioinformatics was carried out to discover the potential targets of TPL in SKOV-3 cells. TPL induces the early apoptosis of SKOV-3 cells in a dose- and time-dependent manner with an IC = 40 ± 0.89 nM when cells are incubated for 48 h. Moreover, 20 nM TPL significantly promotes early apoptosis at a rate of 40.73%. Using a self-designed inverse molecular docking protocol, we fish the top 19 probable targets of TPL from the target library, which was built on 2,250 proteins extracted from the Protein Data Bank. The 2D-DIGE assay reveals that the expression of eight genes is affected by TPL. The results of western blotting and qRT-PCR assay suggest that 40 nM of TPL up-regulates the level of Annexin A5 (6.34 ± 0.07 fold) and ATP syn thase (4.08 ± 0.08 fold) and down-regulates the level of β-Tubulin (0.11 ± 0.12 fold) and HSP90 (0.21 ± 0.09 fold). More details of TPL affecting on Annexin A5 signaling pathway will be discovered in the future. Our results define some potential targets of TPL, with the hope that this agent could be used as therapy for the preclinical treatment of ovarian cancer.

References

Sun Y, Xiao L, Wang D, Ji Y, Yang Y, Ma R . Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. Int J Oncol. 2017; 50(3):847-852. DOI: 10.3892/ijo.2017.3850. View

Zhong Y, Chen H, Tan B, Yu H, Huang X . Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3 platinum-resistant human ovarian cancer cells. Oncol Lett. 2013; 6(4):1084-1092. PMC: 3796418. DOI: 10.3892/ol.2013.1524. View

Lee K, Park J, Jee Y, Rosen G . Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med. 2003; 34(6):462-8. DOI: 10.1038/emm.2002.64. View

Kamper A, Apostolakis J, Rarey M, Marian C, Lengauer T . Fully automated flexible docking of ligands into flexible synthetic receptors using forward and inverse docking strategies. J Chem Inf Model. 2006; 46(2):903-11. DOI: 10.1021/ci050467z. View

Burley S, Berman H, Bhikadiya C, Bi C, Chen L, Di Costanzo L . RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res. 2018; 47(D1):D464-D474. PMC: 6324064. DOI: 10.1093/nar/gky1004. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Kores K, Lesnik S, Bren U, Janezic D, Konc J . Discovery of Novel Potential Human Targets of Resveratrol by Inverse Molecular Docking. J Chem Inf Model. 2019; 59(5):2467-2478. DOI: 10.1021/acs.jcim.8b00981. View

Zhao H, Yang Z, Wang X, Zhang X, Wang M, Wang Y . Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp Mol Med. 2012; 44(11):633-41. PMC: 3509180. DOI: 10.3858/emm.2012.44.11.072. View

Wu J, Li Q, Zhou H, Lu Y, Li J, Ma Y . Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas. Med Oncol. 2014; 31(7):14. DOI: 10.1007/s12032-014-0014-8. View

10.

Nakamura F, Seino M, Suzuki Y, Sakaki H, Sudo T, Ohta T . Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature. J Med Case Rep. 2019; 13(1):328. PMC: 6836488. DOI: 10.1186/s13256-019-2262-x. View

11.

Zhou J, Giannakakou P . Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005; 5(1):65-71. DOI: 10.2174/1568011053352569. View

12.

Li R, Zhang X, Tian X, Shen C, Zhang Q, Zhang Y . Triptolide inhibits tumor growth by induction of cellular senescence. Oncol Rep. 2016; 37(1):442-448. DOI: 10.3892/or.2016.5258. View

13.

Jones G, Willett P, Glen R, Leach A, Taylor R . Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997; 267(3):727-48. DOI: 10.1006/jmbi.1996.0897. View

14.

Vetter M, Hays J . Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. Clin Ther. 2018; 40(3):361-371. DOI: 10.1016/j.clinthera.2018.01.012. View

15.

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Vergote I . A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2017; 14(2):123-136. DOI: 10.2217/fon-2017-0379. View

16.

Crane E, Brown J . Early stage mucinous ovarian cancer: A review. Gynecol Oncol. 2018; 149(3):598-604. DOI: 10.1016/j.ygyno.2018.01.035. View

17.

Cevatemre B, Erkisa M, Aztopal N, Karakas D, Alper P, Tsimplouli C . A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer. Pharmacol Res. 2017; 129:500-514. DOI: 10.1016/j.phrs.2017.11.027. View

18.

Guan J, Zhao Q, Lv J, Zhang Z, Sun S, Mao W . Triptolide induces DNA breaks, activates caspase-3-dependent apoptosis and sensitizes B-cell lymphoma to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors. Oncol Lett. 2017; 14(4):4965-4970. PMC: 5649517. DOI: 10.3892/ol.2017.6771. View

19.

Zhou J, Chang M, Li J, Fang T, Hu J, Bai C . Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest. Respir Res. 2018; 19(1):96. PMC: 5963077. DOI: 10.1186/s12931-018-0804-1. View

20.

Wilson M, Friedlander M, Joly F, Oza A . A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. Oncologist. 2017; 23(2):203-213. PMC: 5813744. DOI: 10.1634/theoncologist.2017-0297. View